Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18851523 | 1.00 | KCNH2 (0.34) | KCNH2GPR119KDM4EPKMPRMT1 | |
| SCHEMBL19455017 | 1.00 | KCNH2 (0.34) | KCNH2GPR119KDM4EPKMPRMT1 | |
| SCHEMBL16659515 | 0.95 | KDM4E (0.33) | GPR119KDM4EPKM | |
| SCHEMBL21285292 | 0.95 | KDM4E (0.33) | GPR119KDM4EPKM | |
| SCHEMBL26258223 | 0.85 | KDM4E (0.35) | KDM4EPKM | |
| SCHEMBL26258627 | 0.85 | KDM4E (0.35) | KDM4EPKM | |
| SCHEMBL8384549 | 0.85 | KDM4E (0.35) | KDM4EPKM | |
| SCHEMBL26050030 | 0.82 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL8344135 | 0.82 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL8166589 | 0.82 | KDM4E (0.32) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | KCNH2 4709/4885GPR119 975/4885KDM4E 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.